The incidence of hepatocellular carcinoma deriving from metabolic dysfunctions has increased in the last years. Sirtuin- (SIRT-3), phospho-mammalian target of rapamycin (p-mTOR) and hypoxia-inducible factor- (HIF-1α) are involved in metabolism and cancer. However, their role in hepatocellular carcinoma (HCC) metabolism, drug resistance and progression remains unclear. This study aimed to better clarify the biological and clinical function of these markers in HCC patients, in relation to the presence of metabolic alterations, metformin therapy and clinical outcome. A total of 70 HCC patients were enrolled: 48 and 22 of whom were in early stage and advanced stage, respectively. The expression levels of the three markers were assessed by immunohistochemistry and summarized using descriptive statistics. SIRT-3 expression was higher in diabetic than non-diabetic patients, and in metformin-treated than insulin-treated patients. Interestingly, p-mTOR was higher in patients with metabolic syndrome than those with different etiology, and, similar to SIRT-3, in metformin-treated than insulin-treated patients. Moreover, our results describe a slight, albeit not significant, benefit of high SIRT-3 and a significant benefit of high nuclear HIF-1α expression in early-stage patients, whereas high levels of p-mTOR correlated with worse prognosis in advanced-stage patients. Our study highlighted the involvement of SIRT-3 and p-mTOR in metabolic dysfunctions that occur in HCC patients, and suggested SIRT-3 and HIF-1α as predictors of prognosis in early-stage HCC patients, and p-mTOR as target for the treatment of advanced-stage HCC.

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin / De Matteis, Serena; Scarpi, Emanuela; Granato, Anna; Vespasiani-Gentilucci, Umberto; La Barba, Giuliano; Foschi, Francesco; Bandini, Erika; Ghetti, Martina; Marisi, Giorgia; Cravero, Paola; Gramantieri, Laura; Cucchetti, Alessandro; Ercolani, Giorgio; Santini, Daniele; Frassineti, Giovanni; Faloppi, Luca; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 20:6(2019), pp. 1-14. [10.3390/ijms20061503]

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin

Scartozzi, Mario;Cascinu, Stefano;Casadei-Gardini, Andrea
2019

Abstract

The incidence of hepatocellular carcinoma deriving from metabolic dysfunctions has increased in the last years. Sirtuin- (SIRT-3), phospho-mammalian target of rapamycin (p-mTOR) and hypoxia-inducible factor- (HIF-1α) are involved in metabolism and cancer. However, their role in hepatocellular carcinoma (HCC) metabolism, drug resistance and progression remains unclear. This study aimed to better clarify the biological and clinical function of these markers in HCC patients, in relation to the presence of metabolic alterations, metformin therapy and clinical outcome. A total of 70 HCC patients were enrolled: 48 and 22 of whom were in early stage and advanced stage, respectively. The expression levels of the three markers were assessed by immunohistochemistry and summarized using descriptive statistics. SIRT-3 expression was higher in diabetic than non-diabetic patients, and in metformin-treated than insulin-treated patients. Interestingly, p-mTOR was higher in patients with metabolic syndrome than those with different etiology, and, similar to SIRT-3, in metformin-treated than insulin-treated patients. Moreover, our results describe a slight, albeit not significant, benefit of high SIRT-3 and a significant benefit of high nuclear HIF-1α expression in early-stage patients, whereas high levels of p-mTOR correlated with worse prognosis in advanced-stage patients. Our study highlighted the involvement of SIRT-3 and p-mTOR in metabolic dysfunctions that occur in HCC patients, and suggested SIRT-3 and HIF-1α as predictors of prognosis in early-stage HCC patients, and p-mTOR as target for the treatment of advanced-stage HCC.
2019
20
6
1
14
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin / De Matteis, Serena; Scarpi, Emanuela; Granato, Anna; Vespasiani-Gentilucci, Umberto; La Barba, Giuliano; Foschi, Francesco; Bandini, Erika; Ghetti, Martina; Marisi, Giorgia; Cravero, Paola; Gramantieri, Laura; Cucchetti, Alessandro; Ercolani, Giorgio; Santini, Daniele; Frassineti, Giovanni; Faloppi, Luca; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea. - In: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. - ISSN 1422-0067. - 20:6(2019), pp. 1-14. [10.3390/ijms20061503]
De Matteis, Serena; Scarpi, Emanuela; Granato, Anna; Vespasiani-Gentilucci, Umberto; La Barba, Giuliano; Foschi, Francesco; Bandini, Erika; Ghetti, Martina; Marisi, Giorgia; Cravero, Paola; Gramantieri, Laura; Cucchetti, Alessandro; Ercolani, Giorgio; Santini, Daniele; Frassineti, Giovanni; Faloppi, Luca; Scartozzi, Mario; Cascinu, Stefano; Casadei-Gardini, Andrea
File in questo prodotto:
File Dimensione Formato  
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 7.46 MB
Formato Adobe PDF
7.46 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1177505
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 22
social impact